PAT-1102

PAT-1102 is a novel, orally bioavailable small molecule histone deacetylase (HDAC) inhibitor developed by Mitra Biotech and Anthem Biosciences. It exhibits pan-HDAC inhibitory activity with preferential selectivity for HDAC-3 and HDAC-6. Mechanistically, PAT-1102 induces histone hyperacetylation, upregulates p21, inhibits angiogenesis, and triggers cell cycle arrest. Preclinical studies in patient-derived refractory solid tumor models (including lung, colorectal, pancreatic, gastric, esophageal, and head and neck cancers) demonstrated potent anti-tumor efficacy, particularly when used in combination with standard-of-care chemotherapeutics. It has shown a favorable pharmacokinetic profile and superior tolerability compared to other HDAC inhibitors like pracinostat in rodent models.